Brainstorm Cell Therapeutics effects 1-for-15 reverse stock split to meet Nasdaq bid price requirement

BRAINSTORM CELL THERAPEUTICS INC.

Reverse stock split at 1:15 ratio effective 11:59 p.m. ET on September 30, 2024.
Trading on split-adjusted basis began October 1, 2024; new CUSIP 10501E300.
Authorized shares unchanged at 250 million; fractional shares paid in cash based on closing price.
Reverse split also applies to warrants, options, and RSUs with proportionate adjustments.
Split intended to increase per share bid price above $1.00 to satisfy Nasdaq continued listing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.